STATEMENT OF TRANSLATIONAL RELEVANCE
MK-2206 is a novel, specific, oral inhibitor of AKT, which is deregulated in multiple cancers. The study of different schedules of targeted agents is critical for their optimal application. The maximum tolerated dose (MTD) of MK-2206 was previously established at 60mg on alternate days (QOD). Due to a long half-life of 60h-80h, MK-2206 was evaluated in a weekly schedule for comparison with QOD dosing in this study. The MK-2206 weekly schedule appeared to be similarly tolerated to QOD dosing, while pharmacodynamic studies using novel quantitative electrochemiluminescence assays in serially-obtained tumor and platelet-rich plasma 
INTRODUCTION
The serine-threonine kinase AKT is a central component of phosphatidylinositol 3-kinase (PI3K)-AKT signaling, and is critical to cell growth, survival, and proliferation [1] . Hyperactivation of this pathway is implicated as a key driver of multiple cancers, including prostate cancer and advanced ovarian tumors [2] . Many castration resistant prostate cancers (CRPC) have genomic abnormalities along the PI3K-AKT pathway, frequently through loss of PTEN, which supports androgen-independent tumor growth [3, 4] . The targeting of AKT in PTEN-loss CRPC tumors is supported by mouse models that indicate that AKT1 loss significantly reduces prostate cancer initiation [5] . The PI3K-AKT pathway is also frequently deranged in ovarian cancer [6] . Genetic amplification and mutation of PIK3CA are observed in approximately 40% and 12% of ovarian cancers, respectively [7, 8] . Similarly, AKT amplification is often encountered in ovarian cancer, although AKT mutations are rare [9, 10] . In view of this, different strategies have been developed to target AKT [2, 11] .
We have previously described the development of the potent, oral, allosteric AKT inhibitor MK-2206 (Merck & Co., Inc., Whitehouse Station, NJ, USA) [12, 13] .
Following the observation of preclinical antitumor activity, a Phase I dose-escalation study of MK-2206 in 33 patients with advanced solid tumors was carried out, which established the maximum tolerated dose (MTD) at 60mg on alternate days (QOD) and demonstrated that MK-2206 safely induced significant AKT pathway blockade in tumor and hair follicles, with preliminary evidence of clinical activity [14] . Functional imaging can also be utilised to evaluate drug PD, including dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion weighted imaging (DWI), proton magnetic resonance spectroscopy ( 1 H-MRS) and intrinsic susceptibility-weighted MR (ISW-MRI) [15] . DCE-MRI is a recognized tool for the characterization of tumor angiogenesis and the quantification of drug effects on tumor vascular permeability and perfusion [16] [17] [18] [19] . DWI is also emerging as a biomarker of tumor necrosis and/or apoptosis [20, 21] . Furthermore, 1 H-MRS can detect decreases in phosphocholine content after PI3K/AKT blockade [22, 23] .
Changes in the imaging parameter for ISW-MRI (R 2 *) after chemotherapy have been described in breast cancers, but the measurement of antitumor changes has not been explored with antitumor targeted agents such as AKT inhibitors [24] . The utilization of these functional imaging techniques allows the characterization of the PD of novel molecular targeted agents in phase I studies.
The study of different schedules of molecularly targeted therapies is critical for their optimal application, but is not often done in randomized phase II trials [25] .
Thus, an alternative strategy is to undertake this during the expansion phase of a phase I clinical trial. In this study, cohorts of patients with CRPC, advanced ovarian cancer, and those undergoing multiparametric MRI studies were treated with 60mg
QOD of MK-2206. In view of a half-life of 60h-80h observed [14] , a QW schedule of MK-2206 was also evaluated to determine the safety and maximum tolerated dose dosing. In addition, electrochemiluminescence assays were utilized to quantify and compare the PD effects of MK-2206 in serial tumour and PRP specimens between both schedules of MK-2206, in parallel with pharmacokinetic (PK) studies.
PATIENTS AND METHODS
This was an open-label, dose-escalation Phase I study of continuous QOD 
Eligibility criteria
Study inclusion criteria included written informed consent; age ≥18 years; patients with histologically or cytologically confirmed advanced solid tumors, who failed to respond to established therapies or for whom no proven treatments existed; Eastern Cooperative Oncology Group (ECOG) performance status [26] ≤1; previous surgery or chemotherapy ≥4 weeks; residual toxicity from prior treatment ≤grade (G)1; adequate bone marrow, renal, and hepatic function; fasting serum glucose ≤1.1x the upper limit of normal (ULN) and HbA1c ≤8%.
Study design
For the QOD study, MK-2206 tablets were administered at 60mg QOD in 28-day cycles to fasted patients in three different cohorts, comprising patients with hematological toxicity, ≥G3 neutropenia with fever, or ≥G3 non-hematological toxicity (except for inadequately-treated G3 nausea, vomiting, or diarrhea).
Safety
Safety assessments were conducted at baseline, days 1, 2, 7, 15, 21, 27, and 28 of cycle 1, weekly in cycle 2 and subsequently every month. All patients had a history, physical examination including full ophthalmologic assessment, electrocardiogram, 24h cardiac Holter monitoring, hematology and chemistry profiling, and urine analysis. In addition to glucose monitoring, serum c-peptide and whole blood HbA1c were measured at baseline and monthly. Adverse events (AEs) and laboratory variables were assessed using CTCAE version 3.0 [28] .
PK Analyses
Plasma concentrations were analyzed by non-compartmental PK methods [29] .
Tumor response
Radiological assessment of disease status was performed at baseline and every 8 weeks, according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [30] . Serum cancer antigen 125 (CA125) was assessed according to Gynecologic Cancer Intergroup (GCIG) criteria [31] and prostate specific antigen (PSA) according to the Prostate Cancer Working Group criteria (PCWG2) [32] .
MRI Methodology
Patients were studied using a 1.5T Avanto MR Siemens system (Siemens 
RESULTS

Seventy
Safety and tolerability
Weekly (QW) schedule dose limiting toxicities (DLTs)
Patients were enrolled into once weekly cohorts of 90mg Three patients discontinued MK-2206 for drug-related AEs of G3 rash (n=1), G3 complete atrioventricular block (n=1), and G1 rash (n=1). Eleven of 33 patients interrupted study therapy due to drug-related AEs. Of these 11 patients, 2 patients resumed therapy at the same dose, 2 patients withdrew consent and did not resume study, and 7 patients required dose reduction to the next lower dose level. Dose interruptions of one day to 4 weeks was required prior to re-initiating study therapy.
Alternate day (QOD) schedule DLTs
DLTs occurred in 7 of 38 (18.4%) patients and included G3 rash (n=5), G3 rash and G3 stomatitis (n=1), and G3 hyperglycemia (n=1) (Supplementary Table   1 ). One patient discontinued study treatment due to G3 rash; this resolved within one week of stopping MK-2206. Overall, DLTs resulted in dose interruption in 6 patients.
Among these 6 patients, study therapy was resumed within 1-2 weeks at the same dose of 60mg QOD (n=2), a reduced dose of 30mg QOD with subsequent dose escalation to 45mg QOD (n=2), and a reduced dose of 50mg QOD (n=1); dose interruption was followed by MK-2206 discontinuation in one patient due to disease progression. All DLTs resolved to baseline levels within 1-2 weeks of drug interruption; the DLT of G3 hyperglycemia was considered to be resolved with sequelae, as this patient with pre-existing glucose intolerance remained on metformin treatment. 
Alternate day (QOD) schedule safety and tolerability
The safety and tolerability of MK-2206 in a QOD schedule have previously been described in the dose-escalation study; thirty-three patients with advanced solid tumors were treated, with G1-2 rash the most common toxicity observed [14] .
Other MK-2206-associated AEs included fatigue, gastrointestinal toxicities, and hyperglycemia. The QOD expansion cohorts in this study have confirmed that MK-2206 is generally well tolerated in 38 patients at the MTD of 60mg QOD, with a similar toxicity profile to that observed during dose escalation (Supplementary Table   1 ) [14] .
Following the first cycle of treatment, G1-2 hyperglycemia was observed in 7.9% (3/38) of patients, and G3 hyperglycemia was observed in 2.6% (1/38) of patients. While not reported as AEs, blood glucose levels were noted to be elevated after QW dosing of 200mg of MK-2206 (n=17). Accumulation ratios were slightly higher after QW dosing of 135mg MK-2206 (1.91 and 1.95, respectively); this is probably attributable to the low number of patients in the 135mg cohort (n=4).
After QW administration in cycle 1, multiple-dose PK was only evaluable in 1 patient in the 90mg, 150mg, or 250mg dose cohorts, and no patients were evaluable in the 300mg QW dose cohorts. Mean C max levels after 90mg to 250mg multiple QW dose administration (153 to 245 nM) were below the mean C max (365nM) of the noobserved-adverse-effect-level (NOAEL) dose in dogs, while the mean C max after the first dose in the 300mg cohort (466nM) was higher that the C max at the NOAEL dose in dogs. The mean 48h (trough) plasma concentrations after multiple dose administration of 90mg to300mg QW MK-2206 exceeded the prespecified 56.8nM PK target for 70% inhibition of pAKT. After QW 90mg, 135mg, and 200mg QW dosing, the mean C 48h values were 79.3nM, 158nM, and 187nM, respectively.
Alternate day (QOD) schedule pharmacokinetics
The peak plasma concentrations of MK-2206 occurred at median T max of 4h after administration of 60mg MK-2206 QOD in the expansion cohort and the t½ was 64h, which was comparable to the PK values of patients in the dose escalation cohorts (Supplementary Table 2 ; Supplementary Figure 1 ) [14] . The accumulation ratio of MK-2206, assessed as AUC last day :AUC first day ratio, was 3.3, consistent with its elimination t½ and suggests no change in PK of MK-2206 after multiple dosing compared with a single dose. A similar accumulation ratio was observed in the dose escalation cohort [14] . This inhibition of pSer473 AKT was associated with significant decreases in the phosphorylation of downstream substrates pSer9 GSK3β to mean levels of 76.8% at 3h (p=0.009), 67.5% at 6h (p=0.0051), 102.9% at 24h (p=0.87), and 116.1% at 48h (p=0.51) of baseline levels ( Figure 2B3) MK-2206-related hyperglycemia and increased C-peptide levels were observed in most patients in both dosing schedules, consistent with PD inhibition of the AKT target and pathway [36] . These elevations in glucose were mainly mild and transient, suggesting effective homeostatic compensation with raised pancreatic insulin/C-peptide release in response to decreased glucose transport and metabolism due to AKT inhibition [36] . Although the exact mechanism of MK-2206-induced hyperglycemia has not been fully elucidated, blockade of the PI3K pathway with other similar small molecule targeted inhibitors appears to be associated with peripheral insulin resistance, increased gluconeogenesis, and/or hepatic glycogenolysis [39] . potentially reduces the time required for data analysis, but also offers the opportunity to explore tumor heterogeneity using a multiparameter analysis and multisegmentation approach. In our studies, the reproducibility measured was better with the DWI parameter (<10%) in contrast to DCE-MRI, 1 H-MRS and ISW-MRI parameters (all >30%), which is likely to reflect differences in the tumoral characteristics measured and the range of imaging techniques employed.
Pharmacodynamic biomarker analysis
Weekly (QW) schedule pharmacodynamics
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Individual examples of DWI and DCE-MRI responses were recorded
(Supplementary Figures 3-4) ; however, a statistically significant cohort change in the image-derived parameters K trans , ADC, or tCho/Water ratio after administration of MK-2206 was not observed (Supplementary Figure 2) . These observations may be 
due primarily to the dose of 60mg QOD of MK-2206 being insufficient to result in alterations in vascular permeability tumor cellularity, as well as total choline and R 2 * levels that are detectable on the functional imaging undertaken; a higher MTD of 200mg QW of MK-2206 may be necessary to achieve this. Such imaging studies should thus be considered in ongoing phase II trials evaluating this dose and schedule of MK-2206. The variability in baseline measurements for the imaging parameters could also mean that the sample size was inadequate to detect small changes. Furthermore, most of the lesions selected for MRI evaluation demonstrated a slow increase in overall size during the study, indicating a lack of antitumor response to MK-2206 monotherapy and suggesting that biologically significant AKT inhibition was possibly not achieved.
In conclusion, we have used detailed safety, PK, and PD studies to establish the MTD/RP2D of MK-2206 in a QW schedule, which results in significant tumor cell target and pathway blockade while demonstrating tolerability for utility in different 
TABLES
Gastrointestinal disorders 
a All values shown represent number of AEs occurring in ≥2 patients during first cycle, and all cycles (parentheses). If a patient experienced the same AE multiple times (at the same or different grade), the adverse event counted every time it occurred.
No treatment-related G4-5 AEs were observed during the study.
No treatment-related G2, 3 or 4 AEs were observed in the 90mg or 135mg dose cohorts.
b All preferred AE terms with "rash" (e.g. rash macular, rash papular, etc.) were collated into the single term of "Rash".
c Dose-limiting toxicity.
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